LV
Livzon Pharmaceutical Group Inc.
LVZPF · OTC
$5.22 +0.00% (+$0.00)
Market Cap ¥40.6B
P/E Ratio 24.41x
Div. Yield 4.02%
ROE 11.95%
Bulios Fair Price
$4.28
18.0% downside
Current Price
$5.22
Undervalued Fair Value Overvalued
According to Bulios Fair Price, LVZPF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
61 /100
Fair P/E 24.41x
EV/EBITDA 14.74x
P/S 3.81x
Growth
32 /100
Declining EPS growth 3.17%
Rev. growth 2.79%
FCF growth 11.46%
Profitability
93 /100
Strong Gross margin 62.84%
Net margin 15.59%
Op. margin 20.24%
Quality
53 /100
Average ROIC 9.49%
ROE 11.95%
ROA 7.05%
Debt
96 /100
Low Debt/Equity 0.32x
Current ratio 1.55x
Int. coverage 45.56x
Stability
78 /100
Stable Beta 0.24x
Rev. volatility 1.90%
EPS volatility 3.34%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LVZPF
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Daping Liu
Employees
8,878
Headquarters
Zhuhai
Upcoming events
13 OCT
Ex-Dividend
Ex-dividend date
27 OCT
Earnings
Upcoming earnings report
03 NOV
Dividend Payment
Payment date